Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY

NCT04597918 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04597918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04597918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
November 25, 2020
Completion date
December 22, 2022
Enrollment
99 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema